O Ret. no patrimônio de Theratechnologies, Inc. é 25.36%
O retorno sobre o patrimônio é uma medida da lucratividade de um negócio em relação ao valor contábil do patrimônio líquido. É calculado pela divisão do lucro líquido do exercício pelo total do patrimônio líquido.
The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH-1902 for the treatment of triple negative breast cancer; and TH-1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.